Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | CFO and Treasurer | February 25, 2025 | February 27, 2025 |
| Faeth Therapeutics, Inc.FTH · Entity 5029 | Chief Financial Officer | June 29, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,464 |
Ending reported balance
After 2025-02-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-25 · Exercise / conversion · Acquired 8,500 · Balance 110,964 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Row 2 · 2025-02-25 · Sale · Disposed 8,400 · Balance 102,564 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 3 · 2025-02-25 · Sale · Disposed 100 · Balance 102,464 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-06-26 | Direct | 440,170 |
Reported balance
After 2025-02-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-25 · Exercise / conversion · Disposed 8,500 · Balance 440,170 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.
Faeth Therapeutics, Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 46,688 |
Last balance in matching sequence
After 2026-07-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-06-29 · Purchase · Acquired 831 · Balance 33,885 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 2 · 2026-06-30 · Purchase · Acquired 1,910 · Balance 35,795 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 3 · 2026-06-30 · Purchase · Acquired 1,638 · Balance 37,433 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 4 · 2026-06-30 · Purchase · Acquired 4,255 · Balance 41,688 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 5 · 2026-07-01 · Purchase · Acquired 4,400 · Balance 46,088 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 6 · 2026-07-01 · Purchase · Acquired 600 · Balance 46,688 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,549 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 9,910 | $12.64 | $125,262.40 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,246 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 27,627 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 27,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 345 shares acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 277,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009280 · doc4.xml · derivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,893 Underlying: Common Stock · 277,893 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 323,431 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001209191-23-009280 · doc4.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,431 Underlying: Common Stock · 323,431 shares Expires 2033-02-09 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after February 10, 2023, such that all of the shares subject to the option shall be vested and exercisable on February 10, 2027, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 00:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 61,040 | $11.01 | $671,922.22 |
DisclosureSEC source: 0001209191-23-007381 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,184 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F2 · price: Represents the weighted average sale price of the shares sold from $10.61 to $11.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 61,040 | $7.67 | $468,469.79 |
DisclosureSEC source: 0001209191-23-002488 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,224 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F2 · price: Represents the weighted average sale price of the shares sold from $7.37 to $7.87 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 19,678 | $9.40 | $184,985.01 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,264 F4 · price: Represents the weighted average sale price of the shares sold from $9.14 to $9.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,358 Underlying: Common Stock · 3,786 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,965 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,003 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,259 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 10,789 | $9.64 | $104,005.96 |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,942 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 30,467 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 30,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-057984 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 4 shares acquired by the Reporting Person on August 15, 2022 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046735 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,158 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046735 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,781 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046735 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,969 Underlying: Common Stock · 1,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 9,227 | $11.08 | $102,235.16 |
DisclosureSEC source: 0001209191-22-046735 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,260 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 26,680 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 26,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046735 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018591 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,351 Underlying: Common Stock · 24,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018591 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,559 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018591 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,678 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 9,228 | $6.74 | $62,196.72 |
DisclosureSEC source: 0000899243-22-018591 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,807 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 26,680 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 26,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-018591 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:24 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 193,543 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011592 · doc4.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,543 Underlying: Common Stock · 193,543 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs will vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs will vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007030 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007030 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,388 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,020 | $8.84 | $9,016.80 |
DisclosureSEC source: 0000899243-22-007030 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,355 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,487 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-007030 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 505 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2022 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 23:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 15,144 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047180 · doc4.xml · derivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,144 Underlying: Common Stock · 15,144 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 23:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 211,366 | $0.00 Strike: $38.62 | $0.00 |
DisclosureSEC source: 0000899243-21-047180 · doc4.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,366 Underlying: Common Stock · 211,366 shares Expires 2031-12-02 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045259 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,115 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045259 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,098 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,234 | $47.25 | $58,306.50 |
DisclosureSEC source: 0000899243-21-045259 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,382 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,488 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-045259 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033443 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,893 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033443 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,808 Underlying: Common Stock · 1,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,028 | $49.48 | $50,865.44 |
DisclosureSEC source: 0000899243-21-033443 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,128 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,487 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,487 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-033443 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019798 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,671 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019798 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 862 | $53.66 | $46,254.92 |
DisclosureSEC source: 0000899243-21-019798 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,669 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,488 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-019798 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 01:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 8,000 | $62.50 | $500,000.00 |
DisclosureSEC source: 0000899243-21-007227 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,043 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007227 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,227 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 592 | $64.98 | $38,468.16 |
DisclosureSEC source: 0000899243-21-007227 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,043 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 1,710 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 1,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-007227 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 840 shares acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 12,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006433 · doc4.xml · derivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,449 Underlying: Common Stock · 12,449 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The units will vest in 16 equal quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F3 · derivative.expiration_date: The units will vest in 16 equal quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 73,440 | $0.00 Strike: $68.87 | $0.00 |
DisclosureSEC source: 0000899243-21-006433 · doc4.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,440 Underlying: Common Stock · 73,440 shares Expires 2031-02-09 F1 · derivative.exercise_date: The option will vest in 48 equal month installments after February 10, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031555 · doc4.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,937 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F3 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.